

Livdelzi[®] (seladelpar) Coadministration with Budesonide

This document is in response to your request for information regarding Livdelzi® (seladelpar [SEL]) and coadministration with budesonide.

Some data may be outside of the US FDA-approved Prescribing Information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi pi.pdf

PK DDI Evaluation

Drug interaction studies have not been conducted between SEL and budesonide. Based on the PK profile of each active ingredient within SEL and budesonide, a PK interaction would not be predicted. For more information about budesonide, please refer to its product labeling.²

SEL PK¹

DDI Mechanism		SEL
Drug Transporters	P-gp/BCRP	Substrate
	OATP1B1	N/A
	OATP1B3	N/A
	OAT3	Substrate
	MATE-1	N/A
	MATE2-K	N/A
	OAT1	N/A
	OCT1	N/A
	OCT2	N/A
Drug Metabolizing Enzymes	CYP1A2	N/A
	CYP2B6	N/A
	CYP2C8	Substrate
	CYP2C9	Substrate
	CYP2C19	N/A
	CYP2D6	N/A
	CYP3A4	Substrate

Relevant SEL Label Information¹

There is no information in the SEL product labeling about the coadministration of SEL and budesonide. For more information, please refer to Section 7 of the SEL US Prescribing Information (Drug Interactions).

Available Data

There are no Gilead studies evaluating the coadministration of SEL and budesonide.

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and June 13, 2025 using search terms that included Livdelzi, seladelpar, budesonide, and related search terms. No relevant citations were found.

References

- Enclosed. LIVDELZI® (seladelpar) capsules, for oral use. US Prescribing Information. Foster City, CA.
- 2. PULMICORT RESPULES® (budesonide inhalation suspension). US Prescribing Information. Wilmington, DE.

Abbreviations

BCRP=breast cancer resistance protein DDI=drug-drug interaction MATE=multidrug and toxic compound extrusion OAT=organic anion transporter OATP=organic anion transporting polypeptide

OCT=organic cation transporter P-gp=P-glycoprotein PK=pharmacokinetic(s) SEL=seladelpar

Product Label

For the full indication, important safety information, and Boxed Warning(s), please refer to the Epclusa US Prescribing Information available at:

https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety 1-800-445-3235, option 3 or www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by 1-800-FDA-1088 or MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.

LIVDELZI, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2025 Gilead Sciences, Inc.